Gene expression changes in the mesenteric lymph nodes of rats after oral peanut extract exposure

Jonge, Jonathan D. de; Pennings, Jeroen L. A.; Baken, Kirsten; Konings, Joke; Ezendam, Janine; Loveren, Henk Van

doi:10.1080/15476910802586126

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgE is systemically produced during the induction or sensitization phase of FA and later is persistently generated and secreted in the tissue through local allergen challenge [ 58 ]. The induction of specific IgE antibodies is invariably accompanied by production of allergen-specific IgGs, such as IgG1, whose synthesis is also Th2 mediated [ 59 , 60 ]. Both IgE and IgG1 OVA-specific antibodies were produced in rats with FA, as previously reported in murine FA models [ 16 , 61 , 62 ].…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response

et al. 2020

View full text Add to dashboard Cite

Glycomacropeptide (GMP) is a bioactive peptide derived from milk κ-casein with immune-modulatory and anti-inflammatory properties. Food allergy (FA) is an adverse immune reaction with a broad spectrum of manifestations. Allergen intake induces persistent intestinal inflammation and tissue damage. In this study, the anti-allergic activity of GMP was evaluated using a rat ovalbumin (OVA)-induced FA model with gastrointestinal manifestation. Rats were orally GMP treated from 3 days prior and during FA development. The severity of food anaphylaxis and diarrheal episodes, antibody production and histamine level were measured. Histopathological changes, inflammation and predominant cytokine profile at intestine were analyzed. Oral GMP intake decreased clinical signs and diarrhea severity induced by allergen, with a significant reduction in intestinal edema and expression level of IL-1β and TNF-α. Prophylaxis with GMP also diminished serum anti-OVA IgE and IgG1, and histamine levels. GMP treatment markedly decreased eosinophil infiltration, mast cell and goblet cell hyperplasia, total IgE expression in intestine, and prevented histological changes in villi, crypts and internal muscularis layer. The treatment effectively suppressed IL-5, IL-13 and GATA3 expression and skewed the intestinal cytokine profile toward type 1 and regulatory. These results suggest that GMP may protect against FA through down-regulating the type 2 inflammatory response.

show abstract

Section: Discussionmentioning

confidence: 99%

Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response

et al. 2020

View full text Add to dashboard Cite

show abstract

“…As described in previous studies [ 54 ], the i.p. immunization of BN rats with OVA, alum and tBp induces the synthesis of specific antibodies in 100% of the animals, especially those isotypes related to Th2 immune response in rat, such as IgE, IgG1 and IgG2a [ 18 , 36 , 58 ]. The anti-OVA antibody profile, including specific IgE, is not surprising and can be attributed to both alum adjuvant and tBp which favor IgE synthesis [ 59 , 60 ].…”

Section: Discussionmentioning

confidence: 99%

“…In this latter condition, Knippels et al have demonstrated oral sensitization and have evaluated the influence of rat strain [ 30 ] and dosage [ 31 , 32 ]. However, the model of oral sensitization without an adjuvant requires a long process of sensitization (six weeks) and, although it has been used in several studies [ 33 – 36 ], success after oral sensitization was not always achieved in a high percentage of rats [ 37 ] and/or the sensitization does not always induce the synthesis of IgE antibodies [ 20 , 30 , 38 , 39 ]]. This limitation makes it difficult to use this model for the screening of new therapies or allergenicity studies.…”

Section: Introductionmentioning

confidence: 99%

Development and Characterization of an Effective Food Allergy Model in Brown Norway Rats

et al. 2015

View full text Add to dashboard Cite

BackgroundFood allergy (FA) is an adverse health effect produced by the exposure to a given food. Currently, there is no optimal animal model of FA for the screening of immunotherapies or for testing the allergenicity of new foods.ObjectiveThe aim of the present study was to develop an effective and rapid model of FA in Brown Norway rats. In order to establish biomarkers of FA in rat, we compared the immune response and the anaphylactic shock obtained in this model with those achieved with only intraperitoneal immunization.MethodsRats received an intraperitoneal injection of ovalbumin (OVA) with alum and toxin from Bordetella pertussis, and 14 days later, OVA by oral route daily for three weeks (FA group). A group of rats receiving only the i.p. injection (IP group) were also tested. Serum anti-OVA IgE, IgG1, IgG2a, IgG2b and IgA antibodies were quantified throughout the study. After an oral challenge, body temperature, intestinal permeability, motor activity, and mast cell protease II (RMCP-II) levels were determined. At the end of the study, anti-OVA intestinal IgA, spleen cytokine production, lymphocyte composition of Peyer’s patches and mesenteric lymph nodes, and gene expression in the small intestine were quantified.ResultsSerum OVA-specific IgG1, IgG2a and IgG2b concentrations rose with the i.p. immunization but were highly augmented after the oral OVA administration. Anti-OVA IgE increased twofold during the first week of oral OVA gavage. The anaphylaxis in both IP and FA groups decreased body temperature and motor activity, whereas intestinal permeability increased. Interestingly, the FA group showed a much higher RMCP II serum protein and intestinal mRNA expression.ConclusionsThese results show both an effective and relatively rapid model of FA assessed by means of specific antibody titres and the high production of RMCP-II and its intestinal gene expression.

show abstract

“…Most importantly, it should discriminate a high percentage of known allergic proteins from non-allergenic proteins and predict their allergenicity (Aldemir, Bars, & Herouet-Guicheney, 2009). And to date several attempts have been made to this end (Akiyama et al, 2001;Bfgh et al, 2009;de Jonge et al, 2008;Dearman et al, 2003;Feng & Collins, 1999;Gaudry et al, 2004;Hilton, Dearman, Sattar, Basketter, & Kimber, 1997;Huang, Zhong, Cai, & Zhang, 2009;Kimber, Betts, & Dearman, 2003;Knippels, Houben, Spanhaak, & Penninks, 1999;Knippels, Penninks, Spanhaak, & Houben, 1998;Navuluri et al, 2006;Vinje, Larsen, & Lfvik, 2009, 2011. Though there is no animal model validated to be complete ideal so far, many studies have shown that the Brown Norway (BN) rat is a high responder strain and its recognition of induced antibodies to specific protein is comparable with that observed in sera from allergic patients (Knippels et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Allergenicity of recombinant human lactoferrin to an animal model Brown Norway rats

Zhou

Wang

Sun

et al. 2012

Food and Agricultural Immunology

View full text Add to dashboard Cite

2014) Allergenicity of recombinant human lactoferrin to an animal model Brown Norway rats, Food and Agricultural Immunology, 25:1, 34-48,The assessment of allergenicity of recombinant human lactoferrin (rhLF) using an animal model for its extensive use. In this study, 32 Brown Norway (BN) rats were divided into four groups that were exposed to ovalbumin (OVA) (positive control), rhLF, bovine lactoferrin (bLF) and saline (negative control), respectively, with daily intragastric administration for 42 days. The level of specific antibody (IgE, IgG and IgG2a), blood cell counts, blood pressure and pathology of important organs were measured and compared among the groups. OVA stimulated significant higher levels of specific-IgE and eosinophil (EO) counts (p B0.05), lower blood pressure (p B0.05) and more serious lesion in the lung of BN rats compared to the other groups. And the animals did not show obvious humeral, cell-mediated and local allergic response to rhLF and bLF. The results demonstrate a weak allergenicity of rhLF on the animal and reveal its potential value for further identified study.

show abstract

Gene expression changes in the mesenteric lymph nodes of rats after oral peanut extract exposure

Cited by 6 publications

References 24 publications

Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response

Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response

Development and Characterization of an Effective Food Allergy Model in Brown Norway Rats

Allergenicity of recombinant human lactoferrin to an animal model Brown Norway rats

Contact Info

Product

Resources

About